The field of research in bladder cancer has seen significant advances in recent years. Next-
generation sequencing has identified the genes most mutated in bladder cancer. This …

Bladder cancer (BCa) is the most common malignancy of the urinary tract and one of the
most prevalent cancers worldwide. While the clinical approach to BCa has remained largely …

The challenge in bladder cancer is to control superficial disease and prevent its recurrence
or progression. Patients with invasive disease need to be identified earlier, when disease …

Effective management of advanced urothelial bladder cancer is challenging. New
discoveries that improve our understanding of molecular bladder cancer subtypes have …

Bladder cancer remains one of the most deadly and expensive diseases affecting modern
society. The options currently available to patients with muscle-invasive bladder cancer …

Bladder cancer is a significant public health problem responsible for more than 130,000
deaths annually worldwide. Disease prevalence is also remarkable, with more than 500,000 …

Treatment of advanced bladder cancer continues to be challenging. Despite initial high
response rates with conventional cisplatin-based chemotherapy regimens, 5-year survival is …

The aim of the present paper was to review findings from the most relevant studies and to
evaluate the value of current chemotherapy and surgery in advanced unresectable and …

Papillary and invasive cancers of the urinary bladder appear to evolve and progress through
distinct molecular pathways. Invasion in bladder cancer forebodes a graver prognosis, and …

Bladder cancer is the fourth most common cancer and ranks eighth as a cause of death from
cancer among men in the United States. Although guidelines assist in treatment, the art of …